Abstract:Immunosurveillance, which describes the immunologically mediated elimination of transformed cells, has been widely accepted in the context of bladder cancer for many decades with the successful use of Bacillus-Calmette Guerin for superficial bladder cancer since the 1970s. With the emergence of checkpoint inhibitor blockade in the treatment of urothelial cancers, there has been a resurgent interest in the immunology of bladder cancer. The theory of cancer immunoediting proposes that the immune system has both pro-tumorigenic and anti-tumor effects, the balance between the two determining the progression of an individual tumor. However, whilst there is evidence for the action of various immune cell populations in bladder cancer, a cohesive picture of the immune response to bladder cancer and its driving forces are still lacking. Additionally, little is still known about the normal immune landscape of the bladder. Future progress in bladder cancer therapeutic approaches will require a strong foundation in understanding the immunology of this disease. This review considers the evidence for the role of the main immune cell populations, both innate and adaptive, in the immune response to bladder cancer. Recent research and overarching themes in the immune response to bladder cancer are explored. The minimal evidence regarding the normal immune landscape of the human bladder is also summarized to contextualize downstream immune responses. Of specific interest are the innate and myeloid populations, some of which are resident in the human bladder and which have significant effects on downstream adaptive tumor immunity. We discuss factors which restrain the efficacy of populations known to have anti-tumor activity such as cytotoxic T cells, including the constraints on checkpoint blockade. Additionally, the effects on the immune response of tumor intrinsic factors such as the genomic subtype of bladder cancer and the effect of common therapies such as chemotherapy and intravesical Bacillus Calmette-Guerin are considered. A significant theme is the polarization of immune responses within the tumor by a heavily immunosuppressive tumor microenvironment which affects the phenotype of multiple innate and adaptive populations. Throughout, clinical implications are discussed with suggestions for future research directions and therapeutic targeting.

Immunotherapeutic prospects and progress in bladder cancer

Advances and future prospects of immunotherapy in bladder cancer

New progress in immunotherapy of lung cancer

Bladder Cancer: Immunotherapy and Pelvic Lymph Node Dissection

Immunotherapy for urothelial cancer: from BCG to checkpoint inhibitors and beyond.

Advances in Diagnosis and Therapy for Bladder Cancer

Advances in diagnosis and treatment of bladder cancer

Immune Responses in Bladder Cancer-Role of Immune Cell Populations, Prognostic Factors and Therapeutic Implications

E2F3/5/8 serve as potential prognostic biomarkers and new therapeutic direction for human bladder cancer

Advances in bladder cancer biology and therapy

Current status and perspective of the immunotherapy of urologic cancer

Immune status for monitoring and treatment of bladder cancer

Bladder cancer immune-related markers: diagnosis, surveillance, and prognosis

Novel Combination Therapies for the Treatment of Bladder Cancer

Advances in Research on Bladder Cancer Targeting Peptides: a Review

The Current Progress and Future Options of Multiple Therapy and Potential Biomarkers for Muscle-Invasive Bladder Cancer

Mechanisms of immune evasion in bladder cancer

Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy

Screening and Identifying Immune-Related Cells and Genes in the Tumor Microenvironment of Bladder Urothelial Carcinoma: Based on TCGA Database and Bioinformatics

Systemic therapy for bladder cancer finally comes into a new age

Progression in immunotherapy for advanced prostate cancer